ArticleBiochemical pharmacology2025
Retrospective analysis and decentralized distribution to improve the lifecycle of Ah receptor research assets.
Article in Biochemical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Scientific progress benefits from the sharing of "research assets" such as data, reagents, models, and experimental samples. To improve asset shareability, we evaluated the availability, quality, and characterization of recombinant DNA molecules, recombinant mouse models, and tissue samples described by our laboratory in ten publications spanning over thirty years. Employing state-of-the-art molecular technologies, we identified existing samples, updated their localization, generated modern sequences and maps of recombinant models, and ported the associated metadata to an internal blockchain-dependent resource using a standardized description for each asset class. We also created non-fungible tokens representing research assets on the public blockchain network Solana. In addition to providing an audit of previously reported shareable assets and improving the value of recombinant models, this re-analysis also provides evidence for the utility of extant tissue samples that may be difficult and expensive to regenerate. The results demonstrate how retrospective analysis can improve and expand upon the spectrum of shareable research assets through updates on molecular characterization and physical location, as well as improving the availability of biological samples of potential high experimental value. Moreover, the development of a decentralized ledger harboring this revised metadata provides a path to the description and tokenization of scientific assets and provides a strategy to extend the life of scientific assets even after laboratories or sources close.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.